What do systematic reviews say?

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

The review found no eligible studies for this question.

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 95 participants
  Low

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

The review found no eligible studies for this question.

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

The review found no eligible studies for this question.

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

The review found no eligible studies for this question.

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 32 participants
  Low

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

GnRH‐a + ipriflavone showed no clear difference in rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  RR 0.67 [0.44, 1.02]
  1 study · 95 participants
  Low

GnRH‐a + conjugated estrogens vs GnRH‐a ± placebo

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

The review found no eligible studies for this question.

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

The review found no eligible studies for this question.

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

GnRH‐a + medroxyprogesterone acetate may leads to lower rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  RR 0.13 [0.02, 0.84]
  1 study · 16 participants
  Low

GnRH‐a + tibolone vs GnRH‐a ± placebo

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 110 participants
  Low

GnRH‐a + tibolone vs GnRH‐a ± placebo

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 160 participants
  Moderate

GnRH‐a + tibolone vs GnRH‐a ± placebo

• Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 365 participants
  Moderate

DHEA vs placebo or control

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 287 participants
  Moderate

DHEA vs placebo or control

DHEA probably leads to higher side effects (androgenic overall combined with acne) number of events compared with control (placebo or no treatment) (moderate certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 3.77 [1.36, 10.47]
  5 studies · 250 participants
  Moderate

DHEA vs placebo or control

DHEA may leads to higher side effects ‐ androgenic side effects number of events compared with control (placebo or no treatment) (low certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 6.57 [1.37, 31.59]
  1 study · 92 participants
  Low

DHEA vs placebo or control

DHEA showed no clear difference in side effects ‐ acne number of events compared with control (placebo or no treatment) (moderate certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 2.26 [0.56, 9.02]
  4 studies · 158 participants
  Moderate

Interventions to reduce blood loss during myomectomy for fibroids vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions to reduce haemorrhage during myomectomy for fibroids 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions to reduce blood loss during myomectomy for fibroids vs placebo or no treatment

Interventions to reduce blood loss during myomectomy for fibroids showed no clear difference in loop ligation of myoma pseudocapsule plus vasopressin compared with placebo or no treatment (low certainty).

• Interventions to reduce haemorrhage during myomectomy for fibroids 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Low